154 related articles for article (PubMed ID: 37752996)
1. Role of lymphatic invasion in predicting biochemical recurrence after radical prostatectomy.
Chung DH; Han JH; Jeong SH; Yuk HD; Jeong CW; Ku JH; Kwak C
Front Oncol; 2023; 13():1226366. PubMed ID: 37752996
[TBL] [Abstract][Full Text] [Related]
2. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Izol V; Ok F; Aslan G; Akdogan B; Sozen S; Ozden E; Celik O; Muezzinoglu T; Turkeri L; Akdogan N; Baltaci S
Prostate; 2022 May; 82(7):763-771. PubMed ID: 35188993
[TBL] [Abstract][Full Text] [Related]
3. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
[TBL] [Abstract][Full Text] [Related]
4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
5. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
[TBL] [Abstract][Full Text] [Related]
6. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
8. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
9. Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy.
Mandoorah Q; Benamran D; Pinar U; Seisen T; Abdessater M; Iselin C; Rouprêt M
Prog Urol; 2022 Dec; 32(16):1462-1468. PubMed ID: 35941008
[TBL] [Abstract][Full Text] [Related]
10. Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer.
Furubayashi N; Negishi T; Uozumi T; Shiraishi K; Taguchi K; Shimokawa M; Nakamura M
Mol Clin Oncol; 2020 Feb; 12(2):104-110. PubMed ID: 31929879
[TBL] [Abstract][Full Text] [Related]
11. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
[TBL] [Abstract][Full Text] [Related]
12. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase.
Altok M; Chapin BF; Matin SF; Achim MF; Gregg JR; Davis JW
Urology; 2021 Sep; 155():144-151. PubMed ID: 33676955
[TBL] [Abstract][Full Text] [Related]
14. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients.
Fergany A; Kupelian PA; Levin HS; Zippe CD; Reddy C; Klein EA
Urology; 2000 Jul; 56(1):92-5. PubMed ID: 10869632
[TBL] [Abstract][Full Text] [Related]
15. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.
Leyh-Bannurah SR; Budäus L; Zaffuto E; Pompe RS; Bandini M; Briganti A; Montorsi F; Schiffmann J; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2018 Feb; 36(2):81.e17-81.e24. PubMed ID: 29248430
[TBL] [Abstract][Full Text] [Related]
16. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
18. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
[TBL] [Abstract][Full Text] [Related]
19. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer.
Jung JH; Seo JW; Lim MS; Lee JW; Chung BH; Hong SJ; Song JM; Rha KH
J Laparoendosc Adv Surg Tech A; 2012 Oct; 22(8):785-90. PubMed ID: 22967037
[TBL] [Abstract][Full Text] [Related]
20. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.
Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Montorsi F; Saad F; Briganti A; Steuber T; Budäus L; Huland H; Graefen M; Tilki D; Karakiewicz PI
Urol Oncol; 2018 Aug; 36(8):365.e1-365.e7. PubMed ID: 29887241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
